Pharmaceuticals (Sep 2024)

Safety and Efficacy of Extracorporeal Photopheresis for Acute and Chronic Graft-versus-Host Disease

  • Eleni Gavriilaki,
  • Eleni Papchianou,
  • Giorgos Karavalakis,
  • Ioannis Batsis,
  • Alkistis Panteliadou,
  • Andriana Lazaridou,
  • Despina Mallouri,
  • Varnavas Constantinou,
  • Paraskevi Karvouni,
  • Paschalis Evangelidis,
  • Anna Papakonstantinou,
  • Apostolia Papalexandri,
  • Panayotis Kaloyannidis,
  • Nikolaos Spyridis,
  • Zoi Bousiou,
  • Anna Vardi,
  • Evangelia Yannaki,
  • Damianos Sotiropoulos,
  • Ioanna Sakellari

DOI
https://doi.org/10.3390/ph17101279
Journal volume & issue
Vol. 17, no. 10
p. 1279

Abstract

Read online

Background/Objectives: Despite novel biological agents, steroid-dependent or -refractory graft-versus-host disease (GvHD) remains a severe complication of allogeneic hematopoietic cell transplantation (allo-HCT). Extracorporeal photopheresis (ECP) is an alternative, non-immunosuppressive treatment for patients with acute (aGvHD) or chronic (cGvHD) GvHD. The aim of this study was to investigate the safety and efficacy of ECP in the treatment of acute and chronic GvHD; Methods: We prospectively studied 112 patients with cGvHD who received one or more previous lines of treatment and 28 patients with steroid-dependent or refractory grade II-IV aGvHD post-alloHSCT. Results: In terms of severe aGvHD, most of the patients (19/28) responded to ECP treatment, while the five-year overall survival (OS) was 34%. After adjustment for several confounder factors, the reduction in immunosuppression (p = 0.026) and number of ECP sessions (p p = 0.037) and earlier post-transplant GVHD diagnosis (p = 0.001). Over a follow-up period of 45.2 [interquartile range (IQR): 5.6–345.1] months, the 5-year cumulative incidence (CI) of cGvHD-related mortality was 21.2% and was significantly reduced in patients with ECP response (p Conclusions: Our results confirm the safety and efficacy of ECP in patients with GvHD and provide sufficient data for further investigation and the best combination drugs needed such that GvHD will not be the major barrier of allo-HCT in the near future.

Keywords